AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

11 фев 2021 07:00:01 Источник Nasdaq GlobeNewswire

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

26 янв 2021 16:01:00 Источник Nasdaq GlobeNewswire

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

17 янв 2021 10:00:00 Источник Nasdaq GlobeNewswire

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

11 янв 2021 07:00:01 Источник Nasdaq GlobeNewswire